BT44

SKU: orb2900634

Description

BT44 is a selective RET activator. BT44 can penetrate through the blood-brain barrier and can be used for the research of neurodegenerative disorders and diabetes mellitus.

Key Properties

• CAS Number: 924759-42-2
• MW: 577.59
• Purity: >98% (HPLC)
• Formula: C₂₈H₂₇F₄N₃O₄S
• SMILES: O(C)C1=C(C=C(S(=O)(=O)N2CC=3C(CC2)=CC=CC3)C=C1)N4CCN(C(=O)C5=C(C(F)(F)F)C=C(F)C=C5)CC4
• Solubility: In Vitro: DMSO : 62.5 mg/mL (108.21 mM; Ultrasonic (<60°C)

Bioactivity

• In Vivo:
  Animal model: Wistar rats, spinal nerve ligation (SNL) and Streptozotocin (STZ; HY-13753)-induced diabetes mellitus models. Dosage: 5, 12.5 or 25 mg/kg. Administration: Subcutaneous injecton, every second day for 10, 42 or 14 days. Result: Alleviated mechanical allodynia in the SNL animals. Treatment with the dose of 5 mg/kg alleviated mechanical hyperalgesia in the STZ-treated animals, while the 12.5 mg/kg dose was not effective. Concentration of 5 mg/kg attenuated cold allodynia in the STZ-treated animals during the first two weeks while the effect of 12.5 mg/kg was not significant. Animal model: Wistar rats, SNL-induced diabetes mellitus model. Dosage: 12.5 or 25 mg/kg. Administration: Subcutaneous injecton, every second day for 10 days. Result: Led to a significant increase in the number of IB4 expressing neurons in the ipsilateral DRGs. The 12.5 mg/kg dose protected IB4-positive neurons from SNL-induced lesion.
• In Vitro:
  Western blot analysis. Cell line: GFRα3-transfected MG87RET cells. Concentration: 7.5, 18, 35 and 75 μM Incubation time: 15 min. Result: Increased RET and ERK phosphorylation.

Storage & Handling

• Storage: Storage temperature: -20°C. Stability: ≥ 2 years
• Expiration Date: 12 months from date of receipt.
• Disclaimer: For research use only